A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease

Overview

About this study

The purpose of this study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Previous diagnosis of celiac disease based on histology and positive celiac serology.

- HLA-DQ2.5 genotype.

- Gluten-free diet for at least 12 months.

- Negative or weak positive for transglutaminase IgA and negative or weak positive for
DGP-IgA/IgG during screening.

Exclusion Criteria:

- Refractory celiac disease.

- HLA-DQ8 genotype.

- Previous oral gluten challenge within 12 months.

- Selective IgA deficiency.

- Diagnosis of Type-1 diabetes.

- Active gastrointestinal diseases.

- History of dermatitis herpetiformis.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/13/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adam Bledsoe, M.D.

Open for enrollment

Contact information:

Chadrick Hinson

(507) 538-6300

Hinson.Chadrick@mayo.edu

More information

Publications

  • Coeliac disease management is limited to strict adherence to a gluten-free diet with no approved therapies. This first-in-human phase 1 study evaluated the safety and tolerability of KAN-101, a liver-targeting glycosylation signature conjugated to a deaminated gliadin peptide designed to induce immune tolerance to gliadin. Read More on PubMed